工程化细胞因子的研究进展  

Research progress on genetically engineered cytokines

作　　者：侯宗文 黄钰(综述) 史新昌[3] 周勇[3] 张怡轩(审校)[1] HOU Zongwen;HUANG Yu;SHI Xinchang;ZHOU Yong;ZHANG Yixuan(Shenyang Pharmaceutical University,Shenyang 117004,LiaoningProvince,China;不详)

机构地区：[1]沈阳药科大学,辽宁沈阳117004 [2]武昌首义学院,湖北武汉430064 [3]中国食品药品检定研究院卫生部生物技术产品检定方法及其标准化重点实验室,北京100050

出　　处：《中国生物制品学杂志》2023年第11期1383-1390,共8页Chinese Journal of Biologicals

基　　金：国家质量基础设施(National Quality Infrastructure,NQI)资助(2021YFF0600804)。

摘　　要：免疫治疗细胞因子制剂在抗感染、抗肿瘤、抗排斥反应、自身免疫疾病以及组织修复等方面具有重要临床价值,但由于早期细胞因子类制剂体内半衰期短、非特异性以及不利的生物分布引起的不良反应,限制了其临床应用。随着人类对细胞因子-受体相互作用的原理及细胞因子介导的信号通路的深入了解,利用细胞因子工程化进行修饰已成为一种有效的细胞因子设计路线。本文主要对细胞因子的工程化设计技术,如重组细胞因子的设计、靶向、递送和mRNA表达、细胞技术,以及未来细胞因子工程化可能的发展方向及其临床转化过程中面临的挑战等作一综述,旨在为细胞因子基因工程化技术的研发提供相关技术参考。Immunotherapy cytokine preparations have important clinical value in anti-infection,anti-tumor,anti-rejection,autoimmune diseases and tissue repair,while their clinical application is limited due to the adverse reactions caused by short half-life,non-specific and adverse biodistribution of early cytokine preparations.With the in-depth understanding of the principle of cytokine-receptor interaction and cytokine-mediated signaling pathways,cytokine engineering for modification has become an effective cytokine design route.This paper mainly summarized the engineering design technology of cytokines,such as the design,targeting and delivery of recombinant cytokines,mRNA expression and cell technology,as well as the possible development directions of cytokine engineering in the future and the challenges in the process of clinical transformation,aiming to provide relevant technical references for the research and development of cytokine genetic engineering technology.

关 键 词：细胞因子 工程化 靶向递送 免疫治疗 

分 类 号：R979.9[医药卫生—药品]